MA30044B1 - Procede de traitement - Google Patents

Procede de traitement

Info

Publication number
MA30044B1
MA30044B1 MA31021A MA31021A MA30044B1 MA 30044 B1 MA30044 B1 MA 30044B1 MA 31021 A MA31021 A MA 31021A MA 31021 A MA31021 A MA 31021A MA 30044 B1 MA30044 B1 MA 30044B1
Authority
MA
Morocco
Prior art keywords
ocular neovascular
administration
treating
methods
derivatives
Prior art date
Application number
MA31021A
Other languages
English (en)
Inventor
Mark Levick
William Henry Miller
Richard Anthony Brigandi
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA30044B1 publication Critical patent/MA30044B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des procédés de traitement d'un trouble néovasculaire oculaire chez un mammifère par l'administration de dérivés de pyrimidine, de dérivés de benzodiazépinyle et des compositions pharmaceutiques en contenant. L'invention concerne également des procédés de traitement d'un trouble néovasculaire oculaire par l'administration de l'acide 5-[[4-[(2,3-diméthyl-2H-indazol-6-yl)méthylamino]-2-pyrimidinyl]amino]-2-méthylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroéthyl)-2,3,4,5-tétrahydro-1H-2-benzazépine-4-acétique ou des sels et des solvates de celui-ci. L'invention concerne en outre des thérapies de combinaison pour le traitement de troubles néovasculaires oculaires.
MA31021A 2005-11-29 2008-06-11 Procede de traitement MA30044B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74047805P 2005-11-29 2005-11-29

Publications (1)

Publication Number Publication Date
MA30044B1 true MA30044B1 (fr) 2008-12-01

Family

ID=38037895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31021A MA30044B1 (fr) 2005-11-29 2008-06-11 Procede de traitement

Country Status (27)

Country Link
US (1) US20080293691A1 (fr)
EP (2) EP1968594B1 (fr)
JP (1) JP5180834B2 (fr)
KR (1) KR20080071188A (fr)
CN (1) CN101370505B (fr)
AT (1) ATE482708T1 (fr)
AU (2) AU2006320535B2 (fr)
BR (1) BRPI0619057A2 (fr)
CA (1) CA2631173A1 (fr)
CR (1) CR10010A (fr)
CY (1) CY1111047T1 (fr)
DE (1) DE602006017261D1 (fr)
DK (1) DK1968594T3 (fr)
EA (1) EA016227B1 (fr)
ES (2) ES2392030T3 (fr)
HR (1) HRP20100559T1 (fr)
IL (1) IL191027A0 (fr)
MA (1) MA30044B1 (fr)
MX (1) MX2008006379A (fr)
MY (1) MY144750A (fr)
NO (1) NO20081963L (fr)
NZ (1) NZ568075A (fr)
PL (1) PL1968594T3 (fr)
PT (1) PT1968594E (fr)
SI (1) SI1968594T1 (fr)
UA (1) UA94427C2 (fr)
WO (1) WO2007064752A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711696C (fr) 2008-01-09 2021-10-26 Reza Dana Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires
US8076475B2 (en) 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
CA2757037C (fr) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Administration d'un medicament dans le segment posterieur
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
WO2011050159A1 (fr) * 2009-10-23 2011-04-28 Glaxo Wellcome Manufacturing Pte Ltd Compositions et procédés
WO2011058179A1 (fr) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5-(4-(n-(2,3-diméthyl-2h-indazol-6-yl)-n-méthylamino)pyrimidin-2-ylamino)-2-méthylbenzènesulfonamide
WO2011069053A1 (fr) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Procede de preparation de pazopanip hcl et formes cristallines de pazopanib hcl
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
WO2012019136A2 (fr) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Appareil d'injection et procédé d'administration de médicament
CA2818215C (fr) * 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions et methodes de traitement d'un oedeme oculaire, de neovascularisation et de maladies associees
WO2012068549A2 (fr) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Formulations d'agents thérapeutiques pour des dispositifs implantés
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CA2840491A1 (fr) 2011-06-28 2013-01-03 Bayer Healthcare Llc Composition pharmaceutique topique ophtalmologique contenant du sorafenib
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
WO2013066616A1 (fr) 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Formulation de pazopanib
US20140335083A1 (en) 2011-12-01 2014-11-13 Glaxo Group Limited Methods of treatment and prevention of eye diseases
CN102657655B (zh) * 2012-05-17 2014-05-21 大连理工大学 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用
CN104582685A (zh) 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物
US9802923B2 (en) 2012-12-17 2017-10-31 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2014097152A1 (fr) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Procédé de préparation du pazopanib ou de ses sels
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
EP2968113B8 (fr) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
JP6572201B2 (ja) 2013-03-15 2019-09-04 エアーピオ セラピューティクス インコーポレイテッド 眼疾患を処置するための組成物、製剤、および方法
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
WO2015068175A2 (fr) 2013-11-05 2015-05-14 Laurus Labs Private Limited Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci
WO2015200905A2 (fr) 2014-06-28 2015-12-30 Oligasis, Llc Doubles antagonistes de pdgf/vegf
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
KR20170043655A (ko) 2014-09-09 2017-04-21 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
EP3217924B1 (fr) 2014-11-10 2025-07-16 ForSight Vision4, Inc. Dispositifs expansibles d'administration de médicament
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017120479A1 (fr) * 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Thérapeutique pour maladies immuno-inflammatoires oculaires
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
CN119264274A (zh) 2017-10-12 2025-01-07 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
CA3092588A1 (fr) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Anticorps anti-il-6 et constructions de fusion et conjugues associes
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
DE3905050A1 (de) 1989-02-18 1990-08-30 Lohmann Therapie Syst Lts Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1995003009A1 (fr) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
DE69529572T2 (de) 1994-11-10 2003-06-18 The University Of Kentucky Research Foundation, Lexington Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP1003569B1 (fr) 1997-08-11 2004-10-20 Allergan, Inc. Implant bio-erodable sterile contenant du retinoide a biocompatibilite accrue et methode de preparation
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6660960B2 (en) 1999-12-28 2003-12-09 K. K. Endo Seisakusho Method for manufacturing golf club
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US7592016B2 (en) 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
RU2311892C2 (ru) 2001-08-29 2007-12-10 КАРВАЛХО Рикардо А. П. ДЕ Имплантируемая и герметизируемая система для однонаправленной доставки терапевтических препаратов в ткани
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
AU2003276125B2 (en) * 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
WO2006117666A2 (fr) * 2005-04-29 2006-11-09 Pfizer Inc. Formes posologques, compositions pharmaceutiques et methodes d'administration sous la capsule de tenon

Also Published As

Publication number Publication date
KR20080071188A (ko) 2008-08-01
AU2006320535A1 (en) 2007-06-07
HRP20100559T1 (hr) 2010-11-30
MX2008006379A (es) 2009-03-03
UA94427C2 (ru) 2011-05-10
JP2009517396A (ja) 2009-04-30
WO2007064752A2 (fr) 2007-06-07
EP2329821A1 (fr) 2011-06-08
DK1968594T3 (da) 2010-12-13
CY1111047T1 (el) 2015-06-11
CR10010A (es) 2008-11-03
EP1968594B1 (fr) 2010-09-29
AU2006320535B2 (en) 2010-09-23
HK1121386A1 (en) 2009-04-24
CA2631173A1 (fr) 2007-06-07
IL191027A0 (en) 2009-08-03
SI1968594T1 (sl) 2011-01-31
BRPI0619057A2 (pt) 2011-09-20
MY144750A (en) 2011-10-31
WO2007064752A3 (fr) 2008-08-14
ATE482708T1 (de) 2010-10-15
DE602006017261D1 (de) 2010-11-11
EA200801168A1 (ru) 2008-10-30
EA016227B1 (ru) 2012-03-30
ES2392030T3 (es) 2012-12-04
EP2329821B1 (fr) 2012-08-22
NZ568075A (en) 2010-12-24
CN101370505A (zh) 2009-02-18
JP5180834B2 (ja) 2013-04-10
PL1968594T3 (pl) 2011-03-31
ES2350858T3 (es) 2011-01-27
PT1968594E (pt) 2010-11-18
AU2010249187A1 (en) 2011-01-06
US20080293691A1 (en) 2008-11-27
CN101370505B (zh) 2012-03-21
EP1968594A2 (fr) 2008-09-17
NO20081963L (no) 2008-08-26

Similar Documents

Publication Publication Date Title
NO20081963L (no) Fremgangsmate for behandling
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
TW200716139A (en) Methods and compositions for managing psychotic disorders
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
PL2081435T3 (pl) Inhibitory kinazy tyrozynowej brutona
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
CY1111390T1 (el) Μεθοδος θεραπευτικης αγωγης καρκινου
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2007046868A3 (fr) Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
BR0212175A (pt) Sal de bissulfato de uma 3-fenil-3-dimetilaminoalquil-4,4-dimetilpiperidin-2,6-di ona, composição farmacêutica, uso de um sal de bissulfato de uma 3-fenil-3-dimetilamino-alquil-4,4-dimetilpiperidin-2,6-d iona, e, método para o tratamento ou a profilaxia de um distúrbio afetivo relacionado com a tensão
WO2007063384A3 (fr) Dérivés de pyrimidine pour le traitement de la croissance cellulaire anormale